Report Overview

The Global Mucopolysaccharidosis I drugs market size stood at USD 1.9 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Mucopolysaccharidosis refers to a group of inherited conditions in which the body is unable to properly breakdown mucopolysaccharides, a long chain of sugar molecules that are found in the body. As a result, these sugars build up in cells, blood, and connective tissues, which can lead to several health problems. There are seven forms of mucopolysaccharidosis. Generally, most of the affected people appear healthy at birth and experience a period of normal development, followed by a decline in physical and/or mental function. As the condition progresses, it may affect appearance, physical abilities, organ and system functioning, and in most cases, cognitive development.



Market Drivers

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the mucopolysaccharidosis treatment market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes will spur demand for mucopolysaccharidosis treatment market during the forecast period.

Moreover, the increasing acquisitions and deals between key players will bolster healthy growth of the market. For instance, in April 2019, GC Pharma announced the signing of a licensing deal with Clinigen KK in Japan for their product offering of Hunterase ICV, which is used for the treatment of Mucopolysaccharidosis Type II (Hunter syndrome).

In addition, the increasing R&D by pharmaceutical companies for the mass production of conventional medications or therapies to treat diseases such as heart disease and diabetes along with rare disorders such as the types of mucopolysaccharidosis. This factor will aid the mucopolysaccharidosis treatment market revenue in the foreseeable future.